10 assets in Vaginal Cancer

Therapeutic assets addressing Vaginal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Vaginal Cancer	Christian Hinrichs	P2	BB (65)
Fludarabine Vaginal Cancer	Christian Hinrichs	P2	BB (65)
e7 tcr-t cells Vaginal Cancer	Christian Hinrichs	P2	B (60)
Belzutifan Vaginal Cancer	Dana-Farber Cancer Institute	P2	CCC (53)
Entinostat Vaginal Cancer	National Cancer Institute (NCI)	P1/2	CC (47)
pds01adc Vaginal Cancer	National Cancer Institute (NCI)	P1/2	CC (47)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Vaginal Cancer	National Cancer Institute (NCI)	P1/2	CC (44)
scg142 tcr-t cells Vaginal Cancer	The Affiliated Hospital of Qingdao University	P1	CC (43)
Talazoparib Vaginal Cancer	M.D. Anderson Cancer Center	P1	CC (43)